Novartis

One of the biggest biotech conferences of the year is around the corner. The 59th annual meeting of the American Society of Hematology, or ASH, is Dec. 9-12 in Atlanta. It's likely to serve as a make-or-break catalyst for many companies researching blood-related diseases and disorders. About 3,...

This weekend's Barron's takes a look at why the king of e-commerce must avoid becoming too profitable. Other featured articles offer the prospects for retail stocks that benefit from woes in the sector and a Swiss drug giant with an underappreciated pipeline. The outlook for the...

Steve Scala of Cowen downgraded shares of Novartis AG (ADR) (NYSE: NVS) from Outperform to Market Perform with a price target lowered to $77 from $87 as the company's strengths "now balance its risks." According to Scala's estimates, Novartis' earnings per share growth from...

Short sellers loaded up on this biotech stock in the most recent period. The company announced a license agreement back in December. The share price rose to a new high between the most recent settlement dates. After Conatus Pharmaceuticals Inc (NASDAQ: CNAT) announced a new licensing...

The cover story in this weekend's Barron's examines where to go and not go for yield in 2017. It's Barron's fifth annual assessment of income-producing investments in 10 sectors. Other featured articles offer Barron's latest picks and pans, as well as experts on...

This weekend's Barron's anticipates which stocks will be the winners and which the losers if each presidential candidate wins. Five European stocks with generous but safe yields are also examined. Other featured articles ponder the prospects for an operator of seniors residences...

Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...

Switzerland-based Novartis AG (ADR) (NYSE: NVS) owns a roughly $14 billion stake in rival Roche Holding Ltd. (ADR) (OTC: RHHBY) and is actively shopping for buyers to acquire its stake. According to Reuters, Novartis has been working with bankers to explore the sale of its stake in Roche and would...

Novartis AG (ADR) (NYSE: NVS) announced on Thursday the establishment of FortiHFy, short for Fortifying Heart Failure clinical evidence and patient quality of life. FortiHFy is an umbrella clinical program that consists of over 40 active or planned trials. The global clinical program will result in...

Bayer AG (ADR) (OTC: BAYRY) recently finished a mid-stage trial for a heart failure drug, finerenone, which showed a "striking" decline in deaths. Now, a Reuters article informed that the company will move into a final-stage trial before the end of the year. It should be noted, however...